HIKAL234.10

Hikal Limited

· Pharma & Health
₹ CrorePeersPANACEABIODCALSAIPARENTINDOCOSOLARAWINDLASINDSWFTLABHESTERBIOMcap ₹2,891 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
HIKAL
FY26
PANACEABIO
FY26
DCAL
FY26
SAIPARENT
FY26
Peer
Median
Valuation — at last close
P/E26.88×119.50×73.19×
P/B2.41×2.87×0.39×4.65×2.87× -16%
EV/EBITDA16.16×-501.02×8.12×56.96×8.12× +99%
Market Cap₹2,891 Cr₹2,378 Cr₹2,621 Cr₹2,302 Cr₹2,378 Cr +22%
Growth
Revenue CAGR 3Y-5.40%11.63%6.71%9.17% -159%
Revenue CAGR 5Y-0.09%0.47%8.93%4.70% -102%
Revenue YoY (latest Q)5.89%19.72%-4.29%7.71% -24%
Net Income YoY (latest Q)66.96%-44.44%-347.24%-195.84% +134%
Profitability
EBITDA Margin12.87%-0.73%19.29%10.16%10.16% +27%
Net Income Margin-2.85%-1.12%3.32%3.74%3.32% -186%
Return on Common Equity-4.07%-0.65%1.46%2.88%1.46% -379%
Return on Capital Employed3.36%-4.13%2.36%2.57%2.36% +42%
Return on Assets-2.06%-0.57%0.82%1.00%0.82% -351%
Credit & Quality
Total Debt/Equity0.57×0.03×0.42×0.65×0.42× +36%
Interest Coverage0.91×-6.23×1.30×1.18×1.18× -23%
Scale — latest FY
Revenue / Total Income₹1,713 Cr₹640 Cr₹2,932 Cr₹381 Cr₹640 Cr +168%
Net Income−₹48.8 Cr−₹7.2 Cr₹97.5 Cr₹14.3 Cr₹14.3 Cr -442%
Total Assets₹2,365 Cr₹1,262 Cr₹11,923 Cr₹1,424 Cr₹1,424 Cr +66%
EPS₹-3.96₹-0.88₹6.22₹4.36₹4.36 -191%
Book Value per Share₹97.07₹135.22₹425.82₹112.07₹135.22 -28%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.